An oncolytic adenoviral vector of Smac increases antitumor activity of TRAIL against HCC in human cells and in mice
Zifei Pei, Liang Chu, Weiguo Zou, Zilai Zhang, Songbo Qiu, Rong Qi, Jinfa Gu, Cheng Qian, Xinyuan Liu – 26 April 2004 – Hepatocellular carcinoma (HCC) displays a high resistance to tumor necrosis factor–related apoptosis–inducing ligand (TRAIL)–mediated cell death. To increase sensitivity of HCC cells to TRAIL, we have constructed an oncolytic adenoviral vector (ZD55) and used this vector to deliver second mitochondria‐derived activator of caspases (Smac) and TRAIL genes (ZD55‐Smac and ZD55‐TRAIL, respectively) into HCC cells.